Patients were randomly assigned to one of the following combinations : gemcitabine , 1200 mg/m ( 2 ) days 1 and 8 , every 21 days , for a maximum of six cycles , plus sorafenib , 800 mg/day , until disease progression or unacceptable toxicity ( arm 1 ) ; or erlotinib , 150 mg/day , plus sorafenib , 800 mg/day , until disease progression or unacceptable toxicity ( arm 2 ) .
